众生药业(002317.SZ)：公司正在积极推进ZSP1601片IIb期临床试验

Group 1 - The core viewpoint of the article is that the company, Zhongsheng Pharmaceutical, is actively advancing the Phase IIb clinical trial of ZSP1601 tablets [1] Group 2 - The company is engaging with investors through an interactive platform to provide updates on its clinical trial progress [1]